Related Experiment Videos
Summary
Itraconazole effectively treated progressive human histoplasmosis in an open trial. Most patients achieved clinical cure with minimal side effects, suggesting it as a preferred treatment for immunocompetent individuals.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Human histoplasmosis is a serious fungal infection, particularly in its progressive forms.
- Treatment options for disseminated and chronic histoplasmosis can be limited, especially in immunocompetent patients.
- Itraconazole is a broad-spectrum antifungal agent with potential utility in histoplasmosis management.
Purpose of the Study:
- To evaluate the efficacy and safety of itraconazole in treating progressive forms of human histoplasmosis.
- To assess treatment outcomes in patients with chronic disseminated, chronic pulmonary, and subacute disseminated histoplasmosis.
- To determine the long-term impact of itraconazole therapy on clinical status and immunological markers.
Main Methods:
- A non-comparative, open-label trial involving 32 patients who completed 6 months of itraconazole treatment.
- Patients received 100 mg/day orally for 2 months, followed by 50 mg/day for 4 months.
- Clinical cure, improvement, relapse rates, serological markers (complement fixation titers), skin test conversion, erythrocyte sedimentation rate, and adverse events were monitored.
Main Results:
- Clinical cure was achieved in 29 out of 32 patients; two showed significant improvement.
- No relapses were observed during follow-up exceeding one year in 23 patients.
- Positive immunological responses included decreasing complement fixation titers (19/32), conversion of negative skin tests to positive (8/10), and reduced erythrocyte sedimentation rates (24/32).
- Mild, transient elevations in hepatic enzymes were noted in 9 patients, with no significant long-term adverse effects reported.
Conclusions:
- Itraconazole demonstrated high efficacy and a favorable safety profile in treating progressive human histoplasmosis.
- The drug appears to be a promising and potentially preferred treatment option for immunocompetent patients with this fungal infection.
- Itraconazole therapy led to significant clinical and immunological improvements, supporting its role in managing histoplasmosis.